# EDGAR Filing Document

**Accession Number:** 0001819133
**File Stem:** 0001193125-26-160320
**Filing Date:** 2026-4
**Character Count:** 4699
**Document Hash:** 092ee5e9cb2797427117c862eb3464ff
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-160320.hdr.sgml**: 20260417

**ACCESSION NUMBER**: 0001193125-26-160320

**CONFORMED SUBMISSION TYPE**: DEFA14A

**PUBLIC DOCUMENT COUNT**: 4

**FILED AS OF DATE**: 20260417

**DATE AS OF CHANGE**: 20260417

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Tango Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001819133
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** DEFA14A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39485
- **FILM NUMBER:** 26869411

**BUSINESS ADDRESS:**
- **STREET 1:** 201 BROOKLINE AVENUE
- **STREET 2:** SUITE 901
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02215
- **BUSINESS PHONE:** (857) 320-4900

**MAIL ADDRESS:**
- **STREET 1:** 201 BROOKLINE AVENUE
- **STREET 2:** SUITE 901
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02215

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** BCTG Acquisition Corp.
- **DATE OF NAME CHANGE:** 20200723

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**SCHEDULE 14A INFORMATION** 

**Proxy Statement Pursuant to Section 14(a) of the** 

**Securities Exchange Act of 1934** 

**(Amendment No.)** 

Filed by the Registrant ☒

Filed by a Party other than the Registrant ☐

Check the appropriate box:

☐ Preliminary Proxy Statement

☐ **Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))** 

☐ Definitive Proxy Statement

☒ Definitive Additional Materials

☐ Soliciting Material Pursuant to §240.14a-12

**TANGO THERAPEUTICS, INC.** 

**(Name of registrant as specified in its charter)** 

**(Name of Person(s) Filing Proxy Statement, if other than the Registrant)** 

Payment of Filing Fee (Check all boxes that apply):

☒ No fee required.

☐ Fee paid previously with preliminary materials.

☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

------

TANGO THERAPEUTICS, INC. 201 BROOKLINE AVENUE, SUITE 901 <br> BOSTON, MA 02215

V90761-P50670

![LOGO](g93491dsp2.jpg)

You invested in TANGO THERAPEUTICS, INC. and it's time to vote!

You have the right to vote on proposals being presented at the Annual Meeting. **Important Notice Regarding the Availability of Proxy Materials for the Shareholder Meeting to Be Held on June 4, 2026.**

Get informed before you vote

View the Notice and Proxy Statement and Annual Report online at www.ProxyVote.com OR you can receive a free paper or email copy of the material(s) by requesting them prior to May 21, 2026. If you would like to request a copy of the material(s) for this and/or future shareholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.

![LOGO](g93491dsp2a.jpg)

\*Please check the meeting materials for any special requirements for meeting attendance.

------

**Vote at www.ProxyVote.com** 

**THIS IS NOT A VOTABLE BALLOT** 

This is an overview of the proposals being presented at the upcoming shareholder meeting. Please follow the instructions on the reverse side to vote on these important matters.

---

| | | | |
|:---|:---|:---|:---|
| **Voting Items** | **Voting Items** | **Board**<br> **Recommends** | **Board**<br> **Recommends** |
| 1. | Election of Class II Directors |  |  |
|  | **Company Nominees:** |  |  |
|  1a. | Malte Peters, M.D. | ![LOGO](g93491dsp3.jpg) | **For** |
|  1b. | Kanishka Pothula | ![LOGO](g93491dsp3.jpg) | **For** |
|  1c. | Mace Rothenberg, M.D. | ![LOGO](g93491dsp3.jpg) | **For** |
| 2. | To ratify the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026. | ![LOGO](g93491dsp3.jpg) | **For** |
| 3. | To approve, on a non-binding, advisory basis, the compensation of our named executive officers. | ![LOGO](g93491dsp3.jpg) | **For** |
| &nbsp;&nbsp; **NOTE:** The Board of Directors will consider and act upon such other business as may properly come before the meeting or any adjournment or postponement thereof. | &nbsp;&nbsp; **NOTE:** The Board of Directors will consider and act upon such other business as may properly come before the meeting or any adjournment or postponement thereof. |  |  |

---

Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click "Delivery Settings".

V90762-P50670